Displaying all 10 publications

Abstract:
Sort:
  1. Gornall J
    BMJ, 2015;351:h3649.
    PMID: 26155990 DOI: 10.1136/bmj.h3649
    Matched MeSH terms: Drug Industry/economics*
  2. Dalton R
    Nature, 2004 Feb 12;427(6975):576.
    PMID: 14961086
    Matched MeSH terms: Drug Industry/economics*
  3. Sodahlon Y, Ross DA, McPhillips-Tangum C, Lawrence J, Taylor R, McFarland DA, et al.
    PLoS Negl Trop Dis, 2020 10;14(10):e0008565.
    PMID: 33031387 DOI: 10.1371/journal.pntd.0008565
    Matched MeSH terms: Drug Industry/economics
  4. Komenkul K, Kiranand S
    Inquiry, 2017 01 01;54:46958017727105.
    PMID: 28853306 DOI: 10.1177/0046958017727105
    We examine the evidence from the long-run abnormal returns using data for 76 health care and biopharmaceutical initial public offerings (IPOs) listed in a 29-year period between 1986 and 2014 in the Association of Southeast Asian Nations (ASEAN) countries such as Indonesia, Malaysia, Singapore, Thailand, the Philippines, Vietnam, Myanmar, and Laos. Based on the event-time approach, the 3-year stock returns of the IPOs are investigated using cumulative abnormal return (CAR) and buy-and-hold abnormal return (BHAR). As a robustness check, the calendar-time approach, related to the market model as well as Fama-French and Carhart models, was applied for verifying long-run abnormal returns. We found evidence that the health care IPOs overperform in the long-run, irrespective of the alternative benchmarks and methods. In addition, when we divide our sample into 5 groups by listing countries, our results show that the health care stock prices of the Singaporean firms behaved differently from those of most of the other firms in ASEAN. The Singaporean IPOs are characterized by a worse post-offering performance, whereas the IPOs of Malaysian and Thai health care companies performed better in the long-run.
    Matched MeSH terms: Drug Industry/economics*
  5. Dranitsaris G, Truter I, Lubbe MS
    Eur J Cancer, 2011 Jun;47(9):1299-304.
    PMID: 21493060 DOI: 10.1016/j.ejca.2011.03.015
    Worldwide, prices for cancer drugs have been under downward pressure where several governments have mandated price cuts of branded products. A better alternative to government mandated price cuts would be to estimate a final price based on drug performance, cost effectiveness and a country's ability to pay. We developed a global pricing index for new cancer drugs in patients with metastatic colorectal cancer (mCRC) that encompasses all of these attributes.
    Matched MeSH terms: Drug Industry/economics
  6. Smith RD, Correa C, Oh C
    Lancet, 2009 Feb 21;373(9664):684-91.
    PMID: 19167054 DOI: 10.1016/S0140-6736(08)61779-1
    The World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) set global minimum standards for the protection of intellectual property, substantially increasing and expanding intellectual-property rights, and generated clear gains for the pharmaceutical industry and the developed world. The question of whether TRIPS generates gains for developing countries, in the form of increased exports, is addressed in this paper through consideration of the importance of pharmaceuticals in health-care trade, outlining the essential requirements, implications, and issues related to TRIPS, and TRIPS-plus, in which increased restrictions are imposed as part of bilateral free-trade agreements. TRIPS has not generated substantial gains for developing countries, but has further increased pharmaceutical trade in developed countries. The unequal trade between developed and developing countries (ie, exporting and importing high-value patented drugs, respectively) raises the issue of access to medicines, which is exacerbated by TRIPS-plus provisions, although many countries have not even enacted provision for TRIPS flexibilities. Therefore this paper focuses on options that are available to the health community for negotiation to their advantage under TRIPS, and within the presence of TRIPS-plus.
    Matched MeSH terms: Drug Industry/economics*
  7. Babar ZD, Izham MI
    Public Health, 2009 Aug;123(8):523-33.
    PMID: 19665741 DOI: 10.1016/j.puhe.2009.06.011
    Previous studies on anti-infective and cardiovascular drugs have shown extraordinary price increases following privatization of the Malaysian drug distribution system. Therefore, it was felt that there was a need to undertake a full-scale study to evaluate the effect of privatization of the Malaysian drug distribution system on drug prices.
    Matched MeSH terms: Drug Industry/economics
  8. Baker BK
    PLoS Med, 2016 Mar;13(3):e1001970.
    PMID: 26954325 DOI: 10.1371/journal.pmed.1001970
    Brook Baker describes the potential harms to global health from the Trans Pacific Partnership Agreement and its failure to balance the interests of patients and the public with those of industry.
    Matched MeSH terms: Drug Industry/economics
  9. Patel I, Rarus R, Tan X, Lee EK, Guy J, Ahmad A, et al.
    Indian J Pharmacol, 2015;47(6):585-93.
    PMID: 26729947 DOI: 10.4103/0253-7613.169592
    Comparative effectiveness research (CER) is an important branch of pharmacoeconomics that systematically studies and evaluates the cost-effectiveness of medical interventions. CER plays instrumental roles in guiding government public health policy programs and insurance. Countries throughout the world use different methods of CER to help make medical decisions based on providing optimal therapy at a reduced cost. Expenses to the healthcare system continue to rise, and CER is one-way in which expenses could be curbed in the future by applying cost-effectiveness evidence to clinical decisions. China, India, South Korea, and the United Kingdom are of essential focus because these country's economies and health care expenses continue to expand. The structures and use of CER are diverse throughout these countries, and each is of prime importance. By conducting this thorough comparison of CER in different nations, strategies and organizational setups from different countries can be applied to help guide public health and medical decision-making in order to continue to expand the establishment and role of CER programs. The patient-centered medical home has been created to help reduce costs in the primary care sector and to help improve the effectiveness of therapy. Barriers to CER are also important as many stakeholders need to be able to work together to provide the best CER evidence. The advancement of CER in multiple countries throughout the world provides a possible way of reducing costs to the healthcare system in an age of expanding expenses.
    Matched MeSH terms: Drug Industry/economics
  10. Bailey W, Truong L
    J Southeast Asian Stud, 2001;32(2):173-93.
    PMID: 19192502
    Matched MeSH terms: Drug Industry/economics
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links